HK Stock Market Move | OCUMENSION-B(01477) up over 6%: New drug Zhiweitai approved by the National Drug Administration for the treatment of allergic conjunctivitis, listed on the market.

OCUMENSION-B (01477) rose more than 6%, as of the time of publication, it has risen by 6.41% to 4.65 Hong Kong dollars, with a trading volume of 6.757 million Hong Kong dollars. On the news front, Ocumension Biosciences announced at noon that the application for the market registration of OT-1001 (Zhiweitai), a highly effective and highly selective histamine H-1 receptor antagonist with anti-allergic properties, has recently been approved by the China National Drug Administration Drug Evaluation Center. It is reported that OT-1001 is the first and only eye drop formulation of the antihistamine drug levocetirizine hydrochloride (active ingredient of ZYRTEC), which is currently marketed in the United States for the treatment of eye itching related to allergic conjunctivitis.